Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Clinical response to crizotinib retreatment after acquisition of drug resistance.

× No keyword cloud information.

5 in total

Review 1. ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it.

Authors: Christian Rolfo; Francesco Passiglia; Marta Castiglia; Luis E Raez; Paul Germonpre; Ignacio Gil-Bazo; Karen Zwaenepoel; Annemieke De Wilde; Giuseppe Bronte; Antonio Russo; Jan P Van Meerbeeck; Paul Van Schil; Patrick Pauwels
Journal: Transl Lung Cancer Res Date: 2014-08

2. Tyrosine kinase inhibitors re-treatment beyond progression: choice and challenge.

Authors: Ru Zhang; Lingli Tu; Lan Sun
Journal: J Thorac Dis Date: 2014-06 Impact factor: 2.895

Review 3. Crizotinib: a review of its use in the treatment of anaplastic lymphoma kinase-positive, advanced non-small cell lung cancer.

Authors: James E Frampton
Journal: Drugs Date: 2013-12 Impact factor: 9.546

Review 4. Oncogenic kinase fusions: an evolving arena with innovative clinical opportunities.

Authors: Fabrizio Tabbò; Marco Pizzi; Peter W Kyriakides; Bruce Ruggeri; Giorgio Inghirami
Journal: Oncotarget Date: 2016-05-03

5. Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study.

Authors: Michaël Duruisseaux; Benjamin Besse; Jacques Cadranel; Maurice Pérol; Bertrand Mennecier; Laurence Bigay-Game; Renaud Descourt; Eric Dansin; Clarisse Audigier-Valette; Lionel Moreau; José Hureaux; Remi Veillon; Josiane Otto; Anne Madroszyk-Flandin; Alexis Cortot; François Guichard; Pascaline Boudou-Rouquette; Alexandra Langlais; Pascale Missy; Franck Morin; Denis Moro-Sibilot
Journal: Oncotarget Date: 2017-03-28

5 in total